non-Hodgkin lymphoma of the nasopharynx with rapidly progressive pancytopenia refractory to high-dose methylprednisolone and rituximab. The lymphoma was immunophenotypically CD3 and CD45 positive but CD4, CD8, CD20, CD30 and CD79a negative and was classified as peripheral T-cell NHL, not otherwise specified. Bone marrow histology did not show marrow involvement of the lymphoma at the time of pancytopenia.
The paternal grandmother of the index patient died at the age of 74 from AML. No prior medical history is available. She had conceived eight children. Her first daughter, patient II-1 had recurrent bacterial infections from childhood and a stable leukocytopenia. In her mid-thirties she suffered a disseminated infection with Mycobacterial avium complex and died at the age of 42 due to histiocytosis X. Two younger sisters (paternal aunts of the index patient) died at the ages of 58 and 7, respectively. No medical documentation is available regarding their cause of death. A paternal uncle of the index patient (patient II-8) had been given a diagnosis of Emberger's syndrome presenting as primary lymphedema of the legs with extensive verrucae palmaris. The oldest cousin of the index patient (patient III-2) died at the age of 21 due to AML, without antecedent medical problems. The oldest brother of the index patient (patient III-8) died at the age of 14 from AML.
GATA2 gene analysis was performed using Sanger sequencing of peripheral blood DNA from the index patient and her father. This revealed two novel mutations located within exon 2; both were present in father and daughter. One mutation was caused by the deletion of a single base pair resulting in a frameshift at amino acid 28 (G28fs), the second was a missense mutation (H26P), which was predicted to be 'probably damaging' by PolyPhen2.
This large family is highly illustrative for the clinical variability and difficulty in predicting outcome in GATA2 mutation carriership, due to the presence of all previously reported phenotypes represented in one family with the unique finding of two novel germline mutations in each case screened.
Germline GATA2 mutations were first described as an etiological defect in familial MDS and AML by Hahn et al., 1 where two missense mutations localizing to the second zinc-finger domain were identified amongst pedigrees with familial MDS/AML. In these pedigrees the GATA2 mutation was associated with early onset MDS/AML with poor prognosis without accessory phenotype such as previous immunodeficiency, hematological abnormalities or lymphedema. Our family demonstrates three generations affected by AML, either preceded by myelodysplasia or not. The range of disease latency varies from 14 to 74.
In previously reported cohorts, some patients developed AML with antecedent hematological abnormalities such as monocytopenia or MDS while others developed de novo AML. [1] [2] [3] [4] This demonstrates that GATA2 heterozygosity alone is not sufficient to predict the disease phenotype or its age of onset. The mechanism behind this phenotypical variation is yet unknown although acquisition of additional mutations are likely to be important 'drivers' in initiating leukaemogenesis, one such mutation, ASXL1, has significant prognostic implications. 5 Immunodeficiency is an important feature in families with GATA2 mutations, with its specific susceptibility for infections with intracellular organisms such as atypical mycobacteria and viruses, which is also prominently featured in our family. Adequate GATA2 expression is crucial for myeloid differentiation of hematopoietic stem cells and deficiency leads to profound monocytopenia, necessary for the eradication of intracellular organisms. In most reported patients with DCML and MonoMac, the monocytopenia is accompanied by relative absence of NK-and B-cells while T-cell compartment is functionally and quantitatively unaffected. These findings were also reflected in our index patient where there was NK-and B-cell lymphopenia, without hypogammaglobulinaemia, while T-cell numbers and subsets were present and functional on stimulation with recall antigens.
Another disease entity, also featured in our family in patient II-8, is the occurrence of primary lymphedema, which has independently been reported by two different groups. 4, 6 In a recent article, Kazenwadel et al. 6 demonstrated that wild-type homozygous GATA2 is crucial for lymphoendothelial valve development and that knockdown of GATA2 in lymphatic endothelial valves leads to absent expression of genes important for valve development, thus explaining the mechanism of lymphedema.
The clinical heterogeneity of our pedigree illustrates that the interplay of additional molecular defects is likely to give rise to this striking variation in phenotype. We report for the first time, two novel mutations occurring in all affected cases in this family and also the first description of an aggressive T-cell NHL associated with GATA2 mutations.
GATA2 mutations have only been described recently and pedigrees are rare. For now, clinical management and guidelines for risk stratification and treatment are mostly based on expert opinion. 7 Since the discovery of the genetic defect, many new mutations in GATA2 have been reported but little is known yet about the precise functional effect of each different mutation. No clear relationship between genotype and phenotypical outcome has been described making prediction of clinical course, as well as identifying those who might benefit from early intervention such as allogeneic bone marrow transplantation, very challenging at the least.
The description of this pedigree, clearly illustrates that, even in the case of seemingly sporadic AML, which is most often not a familial disease entity, a thorough family history that goes beyond first-degree relatives and the exclusion of hematological malignancies, is clearly of importance in diagnosing a GATA2 mutation. Furthermore, in patients with a combination of unexplained immune deficiency, monocytopenia, lymphopenia, lymphedema and/or pulmonary defects, GATA2 mutation analysis should be considered. Although uncertainty in predicting clinical outcome of carriers could lead to reluctance in genetic testing, the identification of a germline GATA2 mutation should prevent unnecessary diagnostic procedures or intervention and could ensure regular follow-up with an appropriate management plan should symptoms or signs of disease develop. Also, given the possibility of asymptomatic carriage of first-degree family members, screening for GATA2 mutation should be considered when analyzing siblings as bone marrow donors. It will be a challenge elucidating the molecular effects of GATA2 mutation but a better understanding of phenotypical development is needed to identify those who are at high risk for developing MDS/AML and with this those who would benefit from early intervention. Follow-up of our large cohort might help delineate the phenotypical heterogeneity as all phenotypes are represented in one family affected with two germline mutation.
